https://www.selleckchem.com/
5, P=.045), compared to stable neurotoxicity in the veliparib arm (M difference=-0.2, P=.778). Weakness was the most common treatment-emergent (50%) and moderate to severe (16%) symptom reported, but did not differ between treatment arms. The proportion of adherence to oral therapy in the overall sample was 75%. Three percent of patients reported clinically significant neurotoxicity that was not captured by physician assessment. Neurotoxicity scores were not different between treatment arms. The addition of veliparib to CE appeared tolerable, though
Like
Comment
Share
